Bio-Techne Corp TECH
72.61
0.04
0.06%
as of 25 Sep
- Market cap
- $11.4B
- P/E
- 62.1×
Follow TECH
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Bio-Techne Corp (TECH) Operating cash flow
Bio-Techne Corp's operating cash flow for fiscal 2026 was $292.1M, unchanged from fiscal 2025. Over the past ten years it has ranged from $139.4M (fiscal 2015) to $352.2M (fiscal 2021); the current reading is higher than 75% of that period. Bio-Techne Corp ranks 16th of 613 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Annual
| Period | Operating cash flow | Change |
|---|---|---|
| FY2026 | $292.1M | 1.57% |
| FY2025 | $287.6M | (3.82%) |
| FY2024 | $299.0M | 17.53% |
| FY2023 | $254.4M | (21.79%) |
| FY2022 | $325.3M | (7.64%) |
| FY2021 | $352.2M | 71.61% |
| FY2020 | $205.2M | 12.99% |
| FY2019 | $181.6M | 6.60% |
| FY2018 | $170.4M | 18.54% |
| FY2017 | $143.7M | (0.30%) |
Quarterly
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $95.4M | 10.10% |
| Mar 2026 | $86.7M | 5.16% |
| Dec 2025 | $82.4M | 198.75% |
| Sep 2025 | $27.6M | (71.91%) |
| 42 more quarters | Free account |
Against its own ten years
Low $139.4M
High $352.2M
Ten-year median
$229.8M
Current reading's percentile
75
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. compare | $857.1M |
| HALO Halozyme Therapeutics, Inc. compare | $818.6M |
| TECH Bio-Techne Corp | $292.1M |
| KRYS Krystal Biotech, Inc. compare | $272.3M |
| CORT Corcept Therapeutics Incorporated compare | $109.7M |
| AXSM Axsome Therapeutics, Inc. compare | −$71.3M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$197.7M |
| BBIO BridgeBio Pharma, Inc. compare | −$434.4M |
| SMMT Summit Therapeutics PLC compare | −$458.4M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on TECH
- Revenue
- Net income
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement